Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,420,949 shares of the medical research company's stock after buying an additional 257,462 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.63% of Thermo Fisher Scientific worth $1,259,450,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TMO. Voloridge Investment Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $7,471,000. Worldquant Millennium Advisors LLC raised its position in shares of Thermo Fisher Scientific by 167.2% in the 4th quarter. Worldquant Millennium Advisors LLC now owns 205,529 shares of the medical research company's stock worth $106,922,000 after acquiring an additional 128,611 shares in the last quarter. Waverly Advisors LLC raised its position in shares of Thermo Fisher Scientific by 6.7% in the 4th quarter. Waverly Advisors LLC now owns 21,523 shares of the medical research company's stock worth $11,197,000 after acquiring an additional 1,346 shares in the last quarter. Wesleyan Assurance Society raised its position in shares of Thermo Fisher Scientific by 2,305.1% in the 4th quarter. Wesleyan Assurance Society now owns 7,095 shares of the medical research company's stock worth $3,691,000 after acquiring an additional 6,800 shares in the last quarter. Finally, Willis Johnson & Associates Inc. raised its position in shares of Thermo Fisher Scientific by 20.6% in the 4th quarter. Willis Johnson & Associates Inc. now owns 439 shares of the medical research company's stock worth $229,000 after acquiring an additional 75 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

TMO has been the topic of several research analyst reports. Royal Bank of Canada dropped their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Barclays cut their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $607.43.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. The trade was a 7.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 1.7%

Thermo Fisher Scientific stock traded down $6.95 during trading on Friday, reaching $393.53. 2,318,052 shares of the company were exchanged, compared to its average volume of 1,869,410. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The company has a market capitalization of $148.56 billion, a P/E ratio of 23.81, a PEG ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock's 50 day simple moving average is $442.54 and its two-hundred day simple moving average is $504.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the previous year, the business earned $5.11 earnings per share. The company's revenue for the quarter was up .2% on a year-over-year basis. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.44%. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.